GlassScriptPhysician profile
Shirley M Abraham
NPI 1740453182
$12,575.95
in general payments reported to CMS, 2019-2025
11 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $1,735 · 2021: $7,032 · 2023: $2,600 · 2024: $244 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Food and Beverage | $586.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $7,332.04 | 2019-2021 | |
| Medexus Pharma, INC. | $2,600.00 | 2023 | Ixinity |
| Novo Nordisk INC | $1,576.82 | 2019-2021 | |
| Octapharma USA, INC. | $300.00 | 2019 | |
| Csl Behring | $180.69 | 2019 | |
| Day One Biopharmaceuticals | $125.00 | 2024 | Ojemda |
| Jazz Pharmaceuticals INC. | $124.13 | 2025 | |
| Uswm, LLC | $119.10 | 2024 | Iwilfin |
| Genentech, INC. | $116.41 | 2025 | Hemlibra |
| Syndax Pharmaceuticals, INC. | $101.76 | 2025 | Revuforj |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirley Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.